Turku, Finland-based Biotie Therapies Oyj climbed by more than 9 percent Wednesday on news that its partner H. Lundbeck A/S completed its Phase III development program with nalmefene, a drug aimed at tackling alcohol dependency, and that it plans to file for European approval later this year.